We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+23.73%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$8.79B
AUM Growth
-$8.56B
Cap. Flow
-$9.86B
Cap. Flow %
-112.21%
Top 10 Hldgs %
80.97%
Holding
105
New
4
Increased
25
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$152M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.3M
3
RVMD icon
Revolution Medicines
RVMD
+$59M
4
REPL icon
Replimune Group
REPL
+$57.6M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$9.45B
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$337M
3
ONC
BeOne Medicines Ltd
ONC
+$199M
4
SWTX
SpringWorks Therapeutics
SWTX
+$69.4M
5
ROIV icon
Roivant Sciences
ROIV
+$41.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.37%
2 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.5B
$40.1M 0.46%
3,882,125
– –
JBIO
27
Jade Biosciences
JBIO
$1.22B
$38M 0.43%
48,015
-8,084
-14% -$4.12M
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.48B
$37.8M 0.43%
1,062,123
– –
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.36B
$34.1M 0.39%
3,112,786
+2,063,087
+197% +$14.5M
SERA icon
30
Sera Prognostics
SERA
$82.6M
$32.5M 0.37%
5,434,399
+3,919,057
+259% +$11.4M
BCYC
31
Bicycle Therapeutics
BCYC
$274M
$32.4M 0.37%
1,790,390
+946,576
+112% +$15.7M
IGMS
32
DELISTED
IGM Biosciences
IGMS
$30.7M 0.35%
3,691,011
+533,247
+17% +$3.1M
BMEA icon
33
Biomea Fusion
BMEA
$91.1M
$30.6M 0.35%
2,108,949
– –
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.87B
$27.8M 0.32%
4,916,095
– –
VERV
35
DELISTED
Verve Therapeutics
VERV
$23.6M 0.27%
1,691,530
+275,000
+19% +$3.41M
KRYS icon
36
Krystal Biotech
KRYS
$10.8B
$21.1M 0.24%
169,934
– –
GRCL
37
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$20.9M 0.24%
2,080,000
+1,080,000
+108% +$4.9M
IMVT icon
38
Immunovant
IMVT
$8.04B
$17.9M 0.2%
425,009
– –
TCRX icon
39
TScan Therapeutics
TCRX
$50.1M
$16.2M 0.18%
2,784,792
– –
DAWN
40
DELISTED
Day One Biopharmaceuticals
DAWN
$14.6M 0.17%
1,000,000
– –
DBVT
41
DBV Technologies
DBVT
$806M
$13.9M 0.16%
1,461,426
– –
RLAY icon
42
Relay Therapeutics
RLAY
$4.14B
$12.8M 0.15%
1,160,117
– –
SPRY icon
43
ARS Pharmaceuticals
SPRY
$577M
$11M 0.13%
2,006,451
– –
STOK icon
44
Stoke Therapeutics
STOK
$1.85B
$10.7M 0.12%
2,030,134
+544,219
+37% +$2.33M
TSVT
45
DELISTED
2seventy bio
TSVT
$10.7M 0.12%
2,497,526
– –
INSM icon
46
Insmed
INSM
$22.7B
$10.6M 0.12%
343,000
– –
CLDX icon
47
Celldex Therapeutics
CLDX
$2.94B
$9.82M 0.11%
+247,644
New +$7.28M
PRME icon
48
Prime Medicine
PRME
$556M
$9.11M 0.1%
1,028,466
– –
NGNE icon
49
Neurogene
NGNE
$675M
$8.79M 0.1%
453,516
+148,162
+49% +$2.12M
ADAP
50
DELISTED
Adaptimmune Therapeutics
ADAP
$8.7M 0.1%
10,969,282
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Baker Bros. Advisors held 105 positions worth $8.79B, down 49% from $17.4B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors withdrew a net $9.86B in Q4 2023, closing 21 positions and reducing 11 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $9.45B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock worth $67.8M.

  • Baker Bros. Advisors's largest Q4 2023 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 1,600,000 shares worth $67.8M.
  • Baker Bros. Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $152M increase.
  • Baker Bros. Advisors's biggest Q4 2023 reduction was BeOne Medicines Ltd, cutting an estimated $199M.
  • Baker Bros. Advisors fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $9.45B.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $8.79B portfolio in Q4 2023.
  • Baker Bros. Advisors opened 4 new positions and closed 21 in Q4 2023.
  • Baker Bros. Advisors's portfolio value fell 49% quarter-over-quarter to $8.79B.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.